262 results on '"Pais, Prem"'
Search Results
2. General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
3. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study
4. Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis
5. Secondary prevention with a structured semi-interactive stroke prevention package in INDIA (SPRINT INDIA): a multicentre, randomised controlled trial
6. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
7. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry
8. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
9. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
10. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
11. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
12. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
13. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
14. Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries
15. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
16. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
17. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
18. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial
19. Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI–UnitedHealth Global Health Centers of Excellence Program
20. Characteristics, clinical practice patterns, and outcomes of strokes in India: INSPIRE—A multicentre prospective study.
21. Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
22. Prevalence, treatments and outcomes of coronary artery disease in Indians: A systematic review
23. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
24. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
25. Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
26. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy
27. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
28. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
29. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
30. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
31. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
32. Lipid Profile, Plasma Apolipoproteins, and Risk of a First Myocardial Infarction Among Asians: An Analysis From the INTERHEART Study
33. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction
34. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial.
35. Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD)
36. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study
37. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data
38. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
39. Aspirin and extended-release Dipyridamole versus Clopidogrel for recurrent stroke
40. Telmisartan to prevent recurrent stroke and cardiovascular events
41. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction
42. Tackling the challenge of cardiovascular disease burden in developing countries
43. Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation
44. New evidence for gender disparities in cardiac interventions: ‘CREATE’-ing some clarity
45. Correlation of regional cardiovascular disease mortality in India with lifestyle and nutritional factors
46. Apixaban versus Warfarin in Patients with Atrial Fibrillation
47. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
48. Apixaban in Patients with Atrial Fibrillation
49. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study
50. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.